Skip to main content

OGT Acquires Sense Proteomic

NEW YORK (GenomeWeb News) – Oxford Gene Technology has acquired protein array firm Sense Proteomic for an undisclosed sum.

UK-based Sense Proteomic has identified biomarker panels for a variety of diseases including prostate cancer and lupus. According to OGT, Sense Proteomic's technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and also can be used to monitor response to therapeutic interventions.

"This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance," OGT CEO Mike Evans said in a statement.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.